Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided due to waiver BASKING RIDGE, N.J., May 20, 2024 .
Press release from Companies Publicerat: 2023-12-22 13:33:27 Cessatech A/S: Cessatech announces positive topline data from study 0205 with its lead candidate.
Last participant has been randomised in clinical trial 0205 investigating efficacy and safety of CT001 relative to placebo and two comparative active arms Primary aim is to show that CT001 offers a better pain reduction and safety profile compared to the comparative arms and placebo Top-line results are anticipated during Q4 2023 once data has been analysed